香港股市 將收市,收市時間:4 小時 55 分鐘

Rain Oncology Inc. (RAIN)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
0.8594-0.0024 (-0.28%)
收市:04:00PM EDT
0.9024 +0.04 (+5.00%)
收市後: 04:03PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價0.8618
開市0.8410
買盤0.8410 x 800
賣出價0.9078 x 1100
今日波幅0.8410 - 0.8650
52 週波幅0.8220 - 14.4800
成交量48,462
平均成交量266,946
市值31.261M
Beta 值 (5 年,每月)0.21
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-2.5700
業績公佈日2023年11月08日 - 2023年11月13日
遠期股息及收益率無 (無)
除息日
1 年預測目標價4.55
  • Insider Monkey

    Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript

    Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of Live Site Advisors. Thank you. You may […]

  • Benzinga

    Rain Therapeutics Experimental Cancer Therapy Shows Encouraging Tumor Regression Activity

    Rain Therapeutics Inc (NASDAQ: RAIN) announced preliminary data from Phase 2 basket trial evaluating milademetan for MDM2-amplified advanced solid tumors. "Treatment with milademetan led to tumor regression in patients previously treated with a multitude of therapies across a range of cancers. We look forward to expanding this dataset as the trial continues to enroll," said Avanish Vellanki, co-founder & CEO. Seventeen patients have been enrolled, 15 of whom have been dosed with milademetan. Ten